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Abstract
Invasion of the central nervous system (CNS) by African trypanosomes represents a critical
step in the development of human African trypanosomiasis. In both clinical cases and
experimental mouse infections it has been demonstrated that predisposition to CNS inva-
sion is associated with a type 1 systemic inflammatory response. Using the Trypanosoma
brucei bruceiGVR35 experimental infection model, we demonstrate that systemic delivery
of the counter-inflammatory cytokine IL-10 lowers plasma IFN-γ and TNF-α concentrations,
CNS parasitosis and ameliorates neuro-inflammatory pathology and clinical symptoms of
disease. The results provide evidence that CNS invasion may be susceptible to immunolog-
ical attenuation.
Author Summary
African trypanosomiasis (also known as sleeping sickness) is caused by the protozoan par-
asites Trypanosoma brucei rhodesiense and T.b.gambiense. After infection through the bite
of the tsetse fly vector, parasites initially disseminate in the blood and lymphatic systems,
in what is known as the early or haemolymphatic stage of infection. However, as infection
progresses some parasites enter the brain, initiating the late or meningoencephalitic stage
of infection. This is a critical step in the progression of disease. In rodent model infections,
inflammatory cytokine and chemokine responses associated with infection have been
demonstrated to promote invasion of the brain and we predicted that this process may be
inhibited by administration of the counter-inflammatory cytokine IL-10 during the early
stage of infection. We demonstrate that in IL-10-treated mice, trypanosome invasion of
the brain is diminished and neuro-inflammatory pathology is reduced. As evidence sug-
gests that systemic inflammatory responses are also associated with promotion of CNS
invasion in human patients, we believe that our results offer the possibility of new
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treatments to delay brain involvement and to identify individuals at high risk of neuroin-
flammatory complications.
Introduction
Human African trypanosomiasis (HAT) is caused by two subspecies of Trypanosoma brucei; T.
b. gambiense and T.b.rhodesiense and presents with typically chronic and acute infection pro-
files in West and East Africa respectively. The disease progresses through two clinical stages. In
the early (stage 1; haemolymphatic) stage parasites are primarily located in the blood and lym-
phatic vasculature; in the late (stage 2, meningoencephalitic) stage parasites penetrate the
blood brain barrier and proliferate in the central nervous system (CNS). There is considerable
variation in the tempo of disease progression between and within each of the two subspecies of
Trypanosoma brucei that cause HAT [1].
Invasion of the CNS is a critical stage in disease progression, and an understanding of the
factors that control this process will offer possibilities for therapeutic intervention. The onset
of the CNS stage of HAT has been modelled using experimental mice. It has been demon-
strated that CNS invasion is promoted by a type 1 inflammatory immune response and the
interaction of both TNF-α [2]and IFN-γ and CXCL10 [3]with the brain vascular endothelium.
This clinical relevance of this finding is supported by observations in T.b.rhodesienseHAT
patients, where high systemic IFN-γ levels were associated with late stage diagnosis[4], and
high systemic counter-inflammatory cytokine levels were associated with a delayed onset of the
late stage[5]. The involvement of the host-response in driving disease progression is consistent
also with studies of peripheral pathogenesis in mouse models where a switch from an early
IFN-γ driven Type 1 immune response (essential for initial parasitaemia control) to an IL-10
dominated Type 2 response is essential for extended survival and amelioration of systemic
pathologies such as anaemia, cachexia, and liver necrosis[6]. The importance of IL-10 in con-
trolling systemic inflammatory pathology in the mouse model is evident in the severe outcome
of infections in IL-10 gene deleted mice [6] and conversely in extended survival and the amelio-
ration of inflammatory pathology in chronically infected mice expressing high levels of virally
delivered IL-10 [7]. As systemic (i.v.) delivery of IL-10 has been shown to inhibit inflammatory
responses in clinical trials [8], we aimed to determine if systemic IL-10 treatment in an experi-
mental animal model of HAT could delay the invasion of the CNS by trypanosomes and result
in reduced CNS pathology.
In this study T.b.brucei-infected mice were systemically treated with recombinant murine
IL10[9,10] to test the hypothesis that treatment would reduce pathology and CNS parasite load
in a highly defined model of late stage infection[11].
Materials and Methods
Animals, infections and treatments
All animal procedures were authorised under the Animals (Scientific Procedures) Act 1986,
Home Office Licence PPL60/4414 and approved by the University of Glasgow Ethical Review
Committee. Animal treatments and group sizes are presented in detail in Fig 1. Briefly, 8 groups
of 6 female CD1 mice (Charles River Laboratories, UK) were infected with 2 x 104 Trypano-
soma brucei brucei GVR 35 parasites by intraperitoneal injection (i.p.). 4 of the groups were
given 4μg of recombinant murine IL-10 (PeproTech EC London) i.p. daily for 14 days, begin-
ning on day 17 post-infection. A further 6 groups of uninfected control animals were
Amelioration of T. bruceiCNS Infection
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004201 October 27, 2015 2 / 9
maintained, of which 3 groups were treated with the IL-10 administration regimen described
above. On day 24 post-infection all (infected and control) mice were treated with 40mg/kg
diminazene aceturate i.p. (Berenil, Hoechst, Germany) to exacerbate the CNS inflammatory
reaction. Infection was confirmed by examination of a wet blood film prior to treatment. On
day 31 post-infection the mice were sacrificed and peripheral blood removed from the brain by
transcardial perfusion with 120 mL of sterile saline and the brain excised for further analysis.
Clinical assessment and neuropathological analysis
Each mouse was examined daily to evaluate the degree of clinical impairment using an estab-
lished visual assessment scale [12] that progresses incrementally from 0–6 as the severity of the
clinical response increases.
At necropsy the excised brains were fixed in neutral buffered formalin and embedded in
paraffin wax prior to sectioning. The severity of the neuro-inflammatory reaction was assessed
in haematoxylin and eosin stained sections using a predefined scoring system where 0 indicates
no pathological changes and 4 denotes the presence of a severe meningoencephalitis [12].
Fig 1. Experimental infection design.Mice were infected with T.b.bruceiGVR35 at day 1 (I) and treated with diminazene aceturate (to eliminate the
peripheral infection) at day 24 (B). IL-10 treatment was carried out from day 17–30 (B) and all mice were euthanized at day 31 (K) for analysis of
neuropathology and parasitosis. Uninfected animals following identical regimens to the infected mice were included as controls (U).
doi:10.1371/journal.pntd.0004201.g001
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Quantitative PCR
Trypanosome load within the brain was determined using Taqman real-time PCR as previ-
ously described [13]. Briefly, following sacrifice brains were immediately frozen on solid car-
bon dioxide and stored at -70°C until required. DNA was prepared from a 25 mg sample of
whole brain homogenate (Qiagen, DNeasy Tissue kit). Taqman PCR to detect the trypanosome
Pfr2 gene was performed in a 25 μL reaction mix comprising 1 x Taqman Brilliant II master
mix (Agilent, UK), 0.05 pmol/μL forward primer (CCAACCGTGTGTTTCCTCCT), 0.05 pmol/μL
reverse primer (GAAAAGGTGTCAAACTACTGCCG), 0.1 pmol/μL probe (FAM-
CTTGTCTTCTCCTTTTTTGTCTCTTTCCCCCT-TAMRA) (Eurofins MWGOperon, Germany) and 100 ng
template DNA. The amplification was performed on a MxPro 3005 (Agilent) with a thermal
profile of 95°C for 10 minutes followed by 45 cycles of 95°C for 15 seconds, 60°C for 1 minute
and 72°C for 1 second.
A standard curve was constructed using a serial dilution (range; 1 x 106 to 1 x 101 copies) of
pCR2.1 vector containing the cloned Pfr2 target sequence (Eurofins MWGOperon) and the
trypanosome load within the brain samples was calculated using the MxPro qPCR software
(Agilent).
Cytokine assays
Plasma cytokine concentrations were measured using solid phase sandwich ELISA (BD
OptEIA, B-D Bioscience, Oxford UK) as described in [14]. The detection limits for each assay
were IFN-γ: 10pg/ml, IL-10: 50pg/ml, IL-6: 5pg/ml, TNF-α: 16pg/ml.
Statistical analysis
Univariate analysis of necropsy data was carried out using 1 way ANOVA with Tukey’s post-
hoc test or Student’s t-test as appropriate. Development of clinical impairment was assessed
using 2-way Repeated Measures ANOVA.
Results
IL-10 treatment reduces the development of neuroinflammation and
CNS parasitosis in late stage African trypanosome infection
In the late stage infection model, mice are given a sub-curative treatment with diminazene
aceturate 24 days after-infection with Trypanosoma brucei. This clears (temporarily) the try-
panosomes from the peripheral compartment but allows continued trypanosome proliferation
in the brain to the experimental end point at day 31 post-infection and instigates a severe neu-
roinflammatory reaction[15]. In the IL-10 treatment groups, mice were given 4μg recombinant
murine IL-10 daily from day 17 post-infection. Histological examination of the brains of unin-
fected control mice with or without IL-10 administration indicated no deviation from normal
histology (Fig 2a). While, as expected, both IL-10 treated and untreated infected mice exhibited
significant increases in neuropathology, those treated with systemic IL-10 from day 17 of infec-
tion exhibited a significantly lower neuropathological grade (3.34±0.08) compared to untreated
infected mice (3.87 ± 0.17, mean ± SE, p<0.05 Tukey post-hoc test). Taqman PCR analysis
revealed that IL-10 treatment significantly (p<0.01) reduced the Pfr2 copy number
(7302 ± 2261) detected within the brain of infected animals compared with non-IL10 treated
mice (23507 ± 4863) (Fig 2b).
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IL-10 treatment reduces systemic IFN-γ and TNF-α levels
At the experimental end point plasma samples were taken to determine circulating cytokine
levels. While no significant differences were observed in IL-6 and IL-10 concentrations (S1
Table), the elevation of plasma IFN-γ concentration observed in both infection groups was sig-
nificantly reduced in IL-10-treated infected mice (Fig 3a) and plasma TNF-α concentrations
were reduced to control levels (Fig 3b).
Fig 2. IL-10 administration reduces neuropathology and CNS parasitosis in experimental African trypanosome infection. (a) Neuropathology scores
were measured in infected (n = 5), control (n = 6), infected and IL-10 treated (n = 5) and IL-10 treated controls (n = 6). Data are mean ±SE. *:p<0.05 Tukey
post-hoc test (b) CNS parasitosis in IL-10 treated (n = 6) and untreated infected mice (n = 6) was measured by Q-PCR. Boxes are median and IQR, whiskers
10th and 90th percentile. *:P<0.05 Unpaired t-test with Welch correction.
doi:10.1371/journal.pntd.0004201.g002
Fig 3. Effect IL-10 administration on plasma cytokine concentrations. (a) Plasma IFN-γ and (b) Plasma TNF-α concentrations in infected (n = 17),
control (n = 8), infected and IL-10 treated mice (n = 17) and IL-10 treated controls (n = 8). Data are mean+SE *p<0.05; **:p<0.01 tukey post-hoc test.
doi:10.1371/journal.pntd.0004201.g003
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IL-10 treatment reduces the onset of clinical symptoms
Clinical scores in individual mice were monitored daily (Fig 4). No clinical signs were associ-
ated with the early stages of the experiment. Between days 23 and 27 post infection clinical
signs were noted in both IL-10 treated and non-treated infected animals. However the mean
response in both groups was similar and remained low (<1.5). There was a slight increase in
clinical score at day 28 of infection in the non-treated group, and this then became a marked
and significant increase (Repeated Measures ANOVA Bonferroni post-hoc test) at days 29
(p<0.01), 30 (p<0.01) and 31 (p<0.05). Thus, the infected mice that did not receive IL-10
treatment exhibited a significantly more severe clinical response compared with the IL-10
treated animals after day 29 of infection, while the maximum mean clinical score in the IL-10
treated mice was less than 1.6.
Discussion
Invasion of the CNS is a critical step in the progression and morbidity of human African try-
panosomiasis. Evidence from experimental models suggests that the process depends on a sys-
temic inflammatory response, particularly involving IFN-γ and TNF-α; this is consistent with
the relationship of plasma IFN-γ levels and the development of meningoencephalitic infection
observed in clinical subjects and leads to the prediction that down-regulation of the systemic
inflammatory response would limit the invasion of the CNS and therefore ameliorate CNS
pathology.
Using an established and highly reproducible model of late stage HAT in experimental
mice, we demonstrate that administration of the counter-inflammatory cytokine IL-10 leads to
a decrease in CNS parasite burden and neuropathology. Furthermore, this treatment signifi-
cantly improved the clinical response of the mice to trypanosome infection. Symptomatic ame-
lioration occurs from day 28 of infection, and this is coincident with the time of moderate to
severe neuro-inflammatory response in this experimental model[14]. At the experimental end
point (day 31 post-infection) there was a reduction in perivascular cuffing and encephalitis
contributing to a significantly improved neuropathology score in IL-10 treated mice. This
Fig 4. IL-10 treatment reduces clinical symptoms in late stage model. IL-10 treated (n = 24) and control
(n = 24) were assessed daily for clinical score. Data are mean±SE. No clinical signs were observed before
day 24 post-infection. Significant reduction in clinical score **: p<0.01 *: p<0.05 Bonferonni corrected post
hoc test.
doi:10.1371/journal.pntd.0004201.g004
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probably was a consequence of the lower CNS parasite burden in IL-10 treated mice. IL-10
treated mice also exhibited reductions in systemic plasma IFN-γ and TNF-α concentrations.
The degree of reduction of TNF-α is consistent with previous experimental studies in which
exogenous IL-10 has been used to modulate endotoxic shock[9], and the reduction in IFN-α
concentration is consistent with the known antagonistic role of IL-10 to Th1 cytokine
responses in experimental trypanosomiasis[6]. As the terminal plasma samples were taken 24h
after IL-10 administration, the lack of any additional IL-10 being detected is most likely due to
the rapid turnover of IL-10. This has been demonstrated in humans[16] and experimental
mice where plasma levels have been shown to fall from 250pg/ml to below 30pg/ml in a little as
3 hours [17]. Because IFN-γ and TNF-α promote cellular interactions that facilitate the inva-
sion of the CNS from the vasculature by trypanosomes and thus regulate subsequent parasito-
sis [2,3], we propose that the down-regulation of these cytokines after IL-10 administration is
the primary mechanism underlying the effect of IL-10 treatment observed here. Importantly a
strong association has also been shown in clinical studies of HAT between the probability of
rapid progression to CNS infection and increased plasma IFN-γ concentrations[18], suggesting
that these results may be extrapolated to the development of the meningoencephalitic stage of
the clinical disease.
The application of IL-10 treatment from day 17 of infection in this study is based on patho-
logical and pharmacological evidence that T.brucei GVR35 establishes within the brain paren-
chyma between 14 and 21 days post-infection [19]. There have been recent reports of
trypanosomes in the CNS at very early times after infection in similar experimental models
using intra-vital imaging [20], but the significance of such observations in relation to our study
remain unclear given that infections at an early stage are effectively cleared using drugs (such
as diminazene aceturate) that do not cross the blood brain barrier [19]. While experimental
administration of non-steroidal anti-inflammatory agents [11] and Substance-P antagonists
[21] have previously been shown to reduce neuropathology in this late stage model validating
the principle of inflammatory modulation of meningo-encephalitis, no data on the modulation
of CNS parasitosis were available. Similarly, the concept of IL-10 modulation of systemic
pathology was confirmed by the use of adenoviral vector delivery of IL-10 [7]. Our study dem-
onstrates the potential for modulation of the most critical step in the progression and patho-
genesis of clinical African trypanosome infections, namely the invasion of the CNS and
development of neuropathology, using IL-10. It seems unlikely that this finding could be
directly applied to the treatment of HAT despite the fact that IL-10 therapy is well tolerated
and may be effective in other chronic pathologies involving inflammatory dysregulation[22].
Rather we see these findings as demonstrating the potential for effective treatments using more
refined immuno-therapeutics and further emphasising the importance of host-inflammatory
response polymorphisms in understanding the diverse spectrum of progression observed in
HAT.
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